3.60 -0.09 (-2.44%)
After hours: 6:28PM EDT
|Bid||3.60 x 1100|
|Ask||3.70 x 1100|
|Day's Range||3.38 - 3.75|
|52 Week Range||0.65 - 8.40|
|Beta (3Y Monthly)||1.49|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 31, 2017 - Nov 6, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.00|
Shares of International Business Machines (NYSE: IBM) are down 5% today as the company topped Wall Street expectations for third-quarter earnings but missed Street estimates for revenue. The company reported a total revenue of $18.76 billion, down from $19.15 billion a year ago. Analysts estimated $19.10 billion in revenue for the third quarter. Netflix, Inc. […] The post Stock Market News Daily Roundup October 17 appeared first on Market Exclusive.
NEW YORK, NY / ACCESSWIRE / October 17, 2018 / U.S. equities closed higher on Tuesday, driven by upbeat corporate earnings and strong economic data. According to the Federal Reserve, U.S. industrial production ...
vTv Therapeutics Inc. (VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered treatments for Alzheimer’s disease and diabetes, today announced that it will deliver an oral presentation and present a poster at the 11th Clinical Trials on Alzheimer’s Disease (CTAD) conference on October 24-27, 2018 in Barcelona, Spain. The oral presentation will detail the results from the phase 3 STEADFAST study of azeliragon in patients with mild Alzheimer’s disease.
NEW YORK, NY / ACCESSWIRE / October 15, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on vTv Therapeutics Inc. (VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates. Despite the lack of company news or announced catalyst, VTVT shares have jumped from $.78 per share to the current price of $3.45 thus far in October. Since its recent announcement regarding the topline results from Part B of the STEADFAST Study, VTVT has continued to analyze the results from Parts A and B and are encouraged by its findings.
HENDERSON, NV / ACCESSWIRE / October 10, 2018 / Stocks in the biotech and cannabis industries provide investors the largest gains. That’s why we always have our ear to the ground for the best opportunities ...
NEW YORK, NY / ACCESSWIRE / October 10, 2018 / Trevena shares sank yesterday on remarks from the Food & Drug Administration on the company’s opioid injection. The FDA has said the treatment could lead ...
DYAI has over $40 million in the bank, a stock buyback agreement, and entered into an additional fully funded research collaboration with Sanofi-Aventis to test the feasibility of using C1 to produce multiple genes for vaccine and drug applications. For those that do not know Sanofi-Aventis is over a $100 Billion company that trades on the New York Stock Exchange. DYAI currently has assets on its balance sheet of over $49 Million while only has a market cap of $46 Million.
NEW YORK, NY / ACCESSWIRE / October 3, 2018 / Inovio Pharmaceuticals saw its shares climb over 14% by the close on Tuesday as traders digested positive data that was published in Clinical Cancer Research. ...
vTv Therapeutics Inc. (VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered treatments for Alzheimer’s disease and diabetes, today announced it will be featured as a presenting company at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held September 4-6, 2018, at The St. Regis Hotel in New York City. vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. This release contains forward-looking statements, which involve risks and uncertainties.
vTv Therapeutics (VTVT) delivered earnings and revenue surprises of -16.00% and 0.69%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the High Point, North Carolina-based company said it had a loss of 31 cents. Losses, adjusted for non-recurring costs, came to 29 cents per share. The results fell short of Wall Street ...
vTv Therapeutics Inc. today reported financial results for the second quarter that ended June 30, 2018, and provided an update on recent achievements and upcoming events.
For today, WallStEquities.com assesses vTv Therapeutics Inc. (NASDAQ: VTVT), Voyager Therapeutics Inc. (NASDAQ: VYGR), ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), and Zosano Pharma Corp. (NASDAQ: ZSAN). High Point, North Carolina headquartered vTv Therapeutics Inc.'s stock saw a decline of 3.70%, finishing last Friday's trading session at $1.30. The Company's shares are trading below their 50-day moving average by 19.58%.
Stock Research Monitor: VYGR, VTVT, and ZSAN LONDON, UK / ACCESSWIRE / July 2, 2018 / If you want a free Stock Review on ZIOP sign up now at www.wallstequities.com/registration . WallStEquities.com recalls ...
vTv Therapeutics Inc. (VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease, diabetes and other therapeutic areas, today announced that Company management will present a poster featuring vTv Therapeutics’ liver-selective Glucokinase Activator at the American Diabetes Association’s 78th Scientific Sessions held in Orlando, Fla., June 22–26, 2018. “As the first company to evaluate a Glucokinase Activator in people with type 1 diabetes, we are very excited to be sharing this clinical data at the American Diabetes Association’s 78th Scientific Sessions,” said Carmen Valcarce, Ph.D., executive vice president, chief scientific officer, vTv Therapeutics.
vTv Therapeutics Inc. (VTVT) today announced that results from Part B of the Company’s STEADFAST Study of the investigational medication azeliragon in people with mild Alzheimer’s disease did not meet co-primary efficacy endpoints. The prespecified subgroup consisted of azeliragon-treated patients with maximal azeliragon plasma concentrations of less than 7.5 ng/mL and baseline Mini Mental State Examination (MMSE) scores between 19 and 27, and the endpoints were statistically significant improvement in cognitive or functional outcomes as measured by the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and Clinical Dementia Rating Scale Sum of Boxes (CDR-sb) at 12-months compared to placebo.
vTv Therapeutics Inc. (VTVT) today announced that vTv Therapeutics LLC has entered into an exclusive licensing agreement with Newsoara Biopharma Co., Ltd. for rights to develop and commercialize vTv Therapeutics’ PDE4 Inhibitor program in mainland China, Hong Kong, Macau, Taiwan and other Pacific Rim countries covering Thailand, Vietnam, Indonesia, Malaysia, Philippines, Singapore, Myanmar, Cambodia, Laos, Brunei and South Korea. Under the terms of the agreement, vTv Therapeutics will receive an upfront payment and will be eligible to receive future development and commercialization milestones as well as royalties on sales of approved products. Newsoara will develop HPP737 in the covered territories for respiratory and other inflammatory diseases.
Under evaluation this morning are these four equities: VIVUS Inc. (NASDAQ: VVUS), Voyager Therapeutics Inc. (NASDAQ: VYGR), vTv Therapeutics Inc. (NASDAQ: VTVT), and Zosano Pharma Corp. (NASDAQ: ZSAN). Shares in Campbell, California headquartered VIVUS Inc. plummeted 14.00%, ending Tuesday's trading session at $0.79.
On a per-share basis, the High Point, North Carolina-based company said it had a loss of 30 cents. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...